منابع مشابه
Radiation exposure of the surgeons in sentinel lymph node biopsy
Background: Sentinel node biopsy (SLNB) is the standard of care for breast cancer treatment and it is getting wide acceptance in Iran. The radiation safety of the procedure has been investigated under controlled conditions, but the standard dose of radiotracer and techniques are not always observed in the community setting. The aim of this study was to assess the magnitude of the absor...
متن کاملSentinel lymph node biopsy
Editor—Kell and Kerin wrote about sentinel lymph node biopsy in breast cancer and melanoma. This is a staging procedure with a well established role in breast cancer, reducing the need for dissection of the axillary node. The indications and advantages for sentinel lymph node biopsy in melanoma are not confirmed, and it is certainly not the established treatment implied in the editorial. Sentin...
متن کاملSentinel lymph node biopsy correctly predicts regional lymph node recurrence in trunk malignant melanoma with multiple drainage basins
We report a young male with an initial excisional biopsy report of melanoma of the lower back, referred to our hospital for complete excision and sentinel lymph node (SLN) biopsy. Four peritumoral intradermal Tc-99m phytate injection was performed and SLNs were detected in both axillary and right inguinal regions. On the biopsy only the right axillary SLN was metastatic leading to right axilla...
متن کامل[Sentinel lymph node biopsy in breast neoplasms].
BACKGROUND/AIM Sentinel node (SN) is the first draining node from the malignant tumor site. In the last decade, sentinel node biopsy (SNB) has been introduced as an alternative to axillary dissection in breast cancer. I n patients with negative SNB (sentinel node uninvolved with malignancy) axillary dissection is not recommended. The aim of this stady was defining the indications for SNB, and S...
متن کاملSentinel-lymph-node biopsy for cutaneous melanoma.
Results: Positive SLNs were detected in 39 (15%) of 260 cases, including 0 (0%) of 45 for cutaneous melanomas 1.0 mm thick or less (T1), 21 (18%) of 115 for melanomas 1.01 to 2.0 mm thick (T2), 12 (19%) of 64 for melanomas 2.01 to 4.0 mm thick (T3), and 5 (16%) of 32 for melanomas thicker than 4.0 mm (T4). Median Breslow depths were 1.89 mm for SLN-positive biopsy specimens and 1.50 mm for SLN-...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Clinical Pathology
سال: 1999
ISSN: 0002-9173,1943-7722
DOI: 10.1093/ajcp/112.5.599